Telmisartan, a possible PPAR-δ agonist, reduces TNF-α-stimulated VEGF-C production by inhibiting the p38MAPK/HSP27 pathway in human proximal renal tubular cells

Biochemical and Biophysical Research Communications

Volumn 454, Issue 2, 2014, Pages 320-327

  Kimura, Hideki ^a,b   Mikami, Daisuke ^a   Kamiyama, Kazuko ^a   Sugimoto, Hidehiro ^b   Kasuno, Kenji ^a   Takahashi, Naoki ^a   Yoshida, Haruyoshi ^a,c   Iwano, Masayuki ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b UNIVERSITY OF FUKUI HOSPITAL   (Japan)

^c Obama Municipal Hospital   (Japan)

Author keywords

HSP27; p38MAPK; PPAR; Telmisartan; TNF ; VEGF C

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN C; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ARTICLE; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY TUBULE CELL; LYMPHANGIOGENESIS; PROTEIN DEPHOSPHORYLATION; AGONISTS; ANTAGONISTS AND INHIBITORS; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KIDNEY PROXIMAL TUBULE; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; CELL LINE; GENE EXPRESSION REGULATION; HSP27 HEAT-SHOCK PROTEINS; HUMANS; KIDNEY TUBULES, PROXIMAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PPAR DELTA; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84909988145     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.10.077     Document Type: Article

References (29)

1. V. Joukov, T. Sorsa, V. Kumar, M. Jeltsch, L. Claesson-Welsh, Y. Cao, O. Saksela, N. Kalkkinen, and K. Alitalo Proteolytic processing regulates receptor specificity and activity of VEGF-C EMBO J. 16 1997 3898 3911
2. M. Jeltsch, A. Kaipainen, V. Joukov, X. Meng, M. Lakso, H. Rauvala, M. Swartz, D. Fukumura, R.K. Jain, and K. Alitalo Hyperplasia of lymphatic vessels in VEGF-C transgenic mice Science 276 1997 1423 1425
3. E. Kukk, A. Lymboussaki, S. Taira, A. Kaipainen, M. Jeltsch, V. Joukov, and K. Alitalo VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development Development 122 1996 3829 3837
4. P. Baluk, T. Tammela, E. Ator, N. Lyubynska, M.G. Achen, D.J. Hicklin, M. Jeltsch, T.V. Petrova, B. Pytowski, S.A. Stacker, S. Yla-Herttuala, D.G. Jackson, K. Alitalo, and D.M. McDonald Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation J. Clin. Invest. 115 2005 247 257
5. Y. Ishikawa, Y. Akishima-Fukasawa, K. Ito, Y. Akasaka, M. Tanaka, R. Shimokawa, M. Kimura-Matsumoto, H. Morita, S. Sato, I. Kamata, and T. Ishii Lymphangiogenesis in myocardial remodelling after infarction Histopathology 51 2007 345 353
6. I. Sakamoto, Y. Ito, M. Mizuno, Y. Suzuki, A. Sawai, A. Tanaka, S. Maruyama, Y. Takei, Y. Yuzawa, and S. Matsuo Lymphatic vessels develop during tubulointerstitial fibrosis Kidney Int. 75 2009 828 838
7. Y. Suzuki, Y. Ito, M. Mizuno, H. Kinashi, A. Sawai, Y. Noda, T. Mizuno, H. Shimizu, Y. Fujita, K. Matsui, S. Maruyama, E. Imai, S. Matsuo, and Y. Takei Transforming growth factor-beta induces vascular endothelial growth factor-C expression leading to lymphangiogenesis in rat unilateral ureteral obstruction Kidney Int. 81 2012 865 879
8. A.S. Lee, J.E. Lee, Y.J. Jung, D.H. Kim, K.P. Kang, S. Lee, S.K. Park, S.Y. Lee, M.J. Kang, W.S. Moon, H.J. Kim, Y.B. Jeong, M.J. Sung, and W. Kim Vascular endothelial growth factor-C and -D are involved in lymphangiogenesis in mouse unilateral ureteral obstruction Kidney Int. 83 2013 50 62
9. A. Ristimaki, K. Narko, B. Enholm, V. Joukov, and K. Alitalo Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C J. Biol. Chem. 273 1998 8413 8418
10. Q. Zhang, R. Guo, Y. Lu, L. Zhao, Q. Zhou, E.M. Schwarz, J. Huang, D. Chen, Z.G. Jin, B.F. Boyce, and L. Xing VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism J. Biol. Chem. 283 2008 13491 13499
11. P.W. Tsai, S.G. Shiah, M.T. Lin, C.W. Wu, and M.L. Kuo Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway J. Biol. Chem. 278 2003 5750 5759
12. A. Machnik, W. Neuhofer, J. Jantsch, A. Dahlmann, T. Tammela, K. Machura, J.K. Park, F.X. Beck, D.N. Muller, W. Derer, J. Goss, A. Ziomber, P. Dietsch, H. Wagner, N. van Rooijen, A. Kurtz, K.F. Hilgers, K. Alitalo, K.U. Eckardt, F.C. Luft, D. Kerjaschki, and J. Titze Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism Nat. Med. 15 2009 545 552
13. C. Ruster, and G. Wolf Renin-angiotensin-aldosterone system and progression of renal disease J. Am. Soc. Nephrol. 17 2006 2985 2991
14. G. Wolf, and E. Ritz Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications Kidney Int. 67 2005 799 812
15. M. Schupp, M. Clemenz, R. Gineste, H. Witt, J. Janke, S. Helleboid, N. Hennuyer, P. Ruiz, T. Unger, B. Staels, and U. Kintscher Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity Diabetes 54 2005 3442 3452
16. M.C. Michel, C. Foster, H.R. Brunner, and L. Liu A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists Pharmacol. Rev. 65 2013 809 848
17. M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity Circulation 109 2004 2054 2057
18. S.C. Benson, H.A. Pershadsingh, C.I. Ho, A. Chittiboyina, P. Desai, M. Pravenec, N. Qi, J. Wang, M.A. Avery, and T.W. Kurtz Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity Hypertension 43 2004 993 1002
19. H. He, D. Yang, L. Ma, Z. Luo, S. Ma, X. Feng, T. Cao, Z. Yan, D. Liu, M. Tepel, and Z. Zhu Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways Hypertension 55 2010 869 879
20. X. Feng, Z. Luo, L. Ma, S. Ma, D. Yang, Z. Zhao, Z. Yan, H. He, T. Cao, D. Liu, and Z. Zhu Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-delta/AMPK pathway J. Cell Mol. Med. 15 2011 1572 1581
21. T. Matsui, S. Yamagishi, S. Ueda, K. Nakamura, T. Imaizumi, M. Takeuchi, and H. Inoue Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation J. Int. Med. Res. 35 2007 482 489
22. Q. Tian, R. Miyazaki, T. Ichiki, I. Imayama, K. Inanaga, H. Ohtsubo, K. Yano, K. Takeda, and K. Sunagawa Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta Hypertension 53 2009 798 804
23. X. Li, H. Kimura, K. Hirota, K. Kasuno, K. Torii, T. Okada, H. Kurooka, Y. Yokota, and H. Yoshida Synergistic effect of hypoxia and TNF-alpha on production of PAI-1 in human proximal renal tubular cells Kidney Int. 68 2005 569 583
24. D. Mikami, H. Kimura, K. Kamiyama, K. Torii, K. Kasuno, N. Takahashi, H. Yoshida, and M. Iwano Telmisartan activates endogenous peroxisome proliferator-activated receptor-delta and may have anti-fibrotic effects in human mesangial cells Hypertens. Res. 37 2014 422 431
25. H. Kimura, X. Li, K. Torii, T. Okada, N. Takahashi, H. Fujii, S. Ishihara, and H. Yoshida A natural PPAR-gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions Nephrol. Dial. Transplant. 23 2008 2496 2503
26. H. Kim, R.P. Kataru, and G.Y. Koh Inflammation-associated lymphangiogenesis: a double-edged sword? J. Clin. Invest. 124 2014 936 942
27. O. Straume, T. Shimamura, M.J. Lampa, J. Carretero, A.M. Oyan, D. Jia, C.L. Borgman, M. Soucheray, S.R. Downing, S.M. Short, S.Y. Kang, S. Wang, L. Chen, K. Collett, I. Bachmann, K.K. Wong, G.I. Shapiro, K.H. Kalland, J. Folkman, R.S. Watnick, L.A. Akslen, and G.N. Naumov Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer Proc. Natl. Acad. Sci. U.S.A. 109 2012 8699 8704
28. Z. Yan, Y. Ni, P. Wang, J. Chen, H. He, J. Sun, T. Cao, J. Chen, Z. Zhao, Z. Luo, L. Chen, D. Liu, and Z. Zhu Peroxisome proliferator-activated receptor delta protects against obesity-related glomerulopathy through the P38 MAPK pathway Obesity (Silver Spring) 21 2013 538 545
29. X. Yang, S. Kume, Y. Tanaka, K. Isshiki, S. Araki, M. Chin-Kanasaki, T. Sugimoto, D. Koya, M. Haneda, T. Sugaya, D. Li, P. Han, Y. Nishio, A. Kashiwagi, H. Maegawa, and T. Uzu GW501516, a PPARdelta agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFkappaB pathway in mice PLoS One 6 2011 e25271